Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The ctDNA for Evaluating Whether to Use Adjuvant Therapy After SBRT in Patients With Early Lung Cancer

NCT05411809 is registered in ClinicalTrials.gov with Peking University Third Hospital as lead sponsor.

NCT NCT05411809
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05411809 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The ctDNA for Evaluating Whether to Use Adjuvant Therapy After SBRT in Patients With Early Lung Cancer
Lead sponsor
Peking University Third Hospital
Phase
Not applicable
Overall status
Not yet recruiting
Start date
June 15, 2022
Completion date
May 15, 2027
Enrollment
180 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

stereotactic body radiation therapy